Zyrova Gold 20 Capsule is a combination pharmaceutical formulation containing Aspirin (75 mg), Rosuvastatin (20 mg), and Clopidogrel (75 mg), indicated for the prevention and management of cardiovascular diseases. Aspirin, an antiplatelet agent, inhibits cyclooxygenase enzymes, thereby reducing thromboxane A2 production and preventing platelet aggregation. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), contributing to the reduction of atherosclerotic plaque formation. Clopidogrel, another antiplatelet agent, selectively inhibits the ADP receptor on platelet cell membranes, further preventing platelet activation and aggregation. The synergistic action of these three agents makes Zyrova Gold 20 Capsule suitable for patients at high risk of ischemic events such as myocardial infarction, stroke, and peripheral arterial disease, especially those with dyslipidemia and a history of thrombotic episodes. It is essential to use this medication under strict medical supervision due to potential adverse effects such as bleeding, myopathy, and hypersensitivity reactions. Regular monitoring of lipid profiles, liver function, and hematological parameters is recommended during therapy to ensure safety and therapeutic efficacy. Zyrova Gold 20 Capsule should be used as part of a comprehensive cardiovascular risk management plan including lifestyle modifications.